Update: chronisch entzündliche Darmerkrankungen

 

 Permissions and Reprints

Zusammenfassung

Morbus Crohn (MC) und Colitis ulcerosa (CU) stellen die beiden Hauptformen der chronisch entzündlichen Darmerkrankungen (CED) dar. Die CED sind klinische Diagnosen, welche durch zusätzliche endoskopische, histologische, radiologische, sonographische und laborchemische Untersuchungs-befunde ergänzt werden. Die CED sind nicht nur auf den GI-Trakt beschränkt, sondern es handelt sich um Systemerkrankungen, welche häufig auch extra-intestinale Manifestationen aufweist. Grundlegendes Behandlungsziel in der medikamentösen Therapie von CED ist die Induktion und dauerhafte Erhaltung einer steroidfreien Remission. Abhängig von der Schwere, der Krankheitsaktivität, dem Befallsmuster und dem bisherigen Krankheitsverlauf wird die Therapieentscheidung getroffen. Der natürliche Verlauf der CED kann sich zwischen den Patienten stark unterscheiden und bedingt daher die Notwendigkeit einer individualisierten Therapieentscheidung.

Abstract

Crohn’s disease and ulcerative colitis are the major entities of inflammatory bowel diseases (IBD). IBD is a clinical diagnosis, which is supported by endoscopic, histologic, radiologic, sonographic and laboratory findings. IBD are not restricted to the GI-tract but are instead systemic diseases that often involve extra-intestinal manifestations. Aim of the rational medical therapy is the induction and maintenance of a steroid-free remission. The medical therapy depends on the severity, activity and extent of disease as well as the disease course of the patient. There is the dire necessity for an individualized therapeutic concept as the natural disease course differs between the patients.

• Literatur

• 1 Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012; 380: 1590-1605
  CrossrefPubMedGoogle Scholar
• 2 Danese S, Fiocchi C. Ulcerative colitis. New Engl J Med 2011; 365: 1713-1725
  CrossrefPubMedGoogle Scholar
• 3 Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A) : 5-36A
  PubMedGoogle Scholar
• 4 Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013; 10: 585-95
  CrossrefPubMedGoogle Scholar
• 5 Preiß JC, Bokemeyer B, Buhr HJ et al. Updated German clinical practice guideline on diagnosis and treatment of crohn’s disease 2014. Z Gastroenterol 2014; 52: 1431-1484
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Dignass A, Preiss JC, Aust DE et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 2011; 49: 1276-1341
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-521
  CrossrefPubMedGoogle Scholar
• 8 Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078
  CrossrefPubMedGoogle Scholar
• 9 Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013; 62: 1505-1510
  CrossrefPubMedGoogle Scholar
• 10 Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329-342
  CrossrefPubMedGoogle Scholar
• 11 Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013; 31: 336-344
  CrossrefPubMedGoogle Scholar
• 12 Kiesslich R, Fritsch J, Holtmann M et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888
  CrossrefPubMedGoogle Scholar
• 13 Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61: 1619-1635
  CrossrefPubMedGoogle Scholar
• 14 Travis SP, Stange EF, Lémann M et al. European Crohn’s and Colitis Organisation (ECCO). European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62
  CrossrefPubMedGoogle Scholar
• 15 Dignass A, Van Assche G, Lindsay JO et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010; 4: 28-62
  CrossrefPubMedGoogle Scholar
• 16 Sandborn WJ, Travis S, Moro L. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: 1218-1226
  CrossrefPubMedGoogle Scholar
• 17 Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63: 433-441
  CrossrefPubMedGoogle Scholar
• 18 Feagan BG, Rutgeerts P, Sands BE et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710
  CrossrefPubMedGoogle Scholar
• 19 Laharie D, Bourreille A, Branche J et al. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
  CrossrefPubMedGoogle Scholar
• 20 Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-1395
  CrossrefPubMedGoogle Scholar
• 21 Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-721
  CrossrefPubMedGoogle Scholar
• 22 Atreya R, Neumann H, Neufert C et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 2014; 20: 313-318
  CrossrefPubMedGoogle Scholar